Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial;¿Mejora el uso de abciximab intracoronario el resultado del intervencionismo percutáneo? Estudio prospectivo y aleatorizado

Revista Espanola de Cardiologia

Volumn 59, Issue 6, 2006, Pages 567-574

  Galache Osuna, José G ^a   Sánchez Rubio, Juan ^a   Calvo, Isabel ^a   Diarte, José A ^a   Lukic, Antonela ^a   Placer, Luis J ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Abciximab; Platelet aggregation; Prospective randomized trial; Stent

Indexed keywords

ABCIXIMAB; TROPONIN; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY; ANGIOCARDIOGRAPHY; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; STENT; TIME; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY VESSELS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746985958     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090138     Document Type: Article

References (28)

1. Topol EJ. Prevention of cardiovascular ischemic complications with new platelet glycoprotein IIb/IIIa inhibitors. Am Heart J. 1995;130:666-72.
2. Genetta TB, Mauro VF. ABCIXIMAB: a new antiaggregant used in angioplasty. Ann Pharmacother. 1996;30:251-7.
3. Galassi AR, Russo G, Nicosia A, Tamburino C, Foti R, Rodi G, et al. Usefulness of platelet glycoprotein IIb/IIIa inhibitors in coronary stenting for reconstruction of complex lesions: procedural and 30 day outcome. Cardiologia. 1999;44:639-45.
4. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. RAPPORT Investigators. Circulation. 1998;98: 734-41.
5. Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gómez Doblas JJ, De Teresa Galván E, et al. ¿El abciximab mejora el pronóstico de los diabéticos tras la intervención coronaria percutánea? Rev Esp Cardiol. 2002;55:810-5.
6. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35:922-8.
7. Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol. 1998;31:31-6.
8. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonier B, et al. Documento de consenso de expertos sobre el uso de agentes antiplaquetarios. Rev Esp Cardiol. 2004;57:963-80.
9. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigators. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA. 1997;278:479-84.
10. Bellandi F, Maioli M, Gallopin M, Tosso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial treated with primary coronary intervention. Catheter Cardiovasc Interv. 2004;62:186-92.
11. Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation. 1998;97:857-64.
12. Foster RH, Weisman LR. Abciximab. An updated review of its use in ischemic heart disease. Drugs. 1998;56:629-65.
13. Silver S, Albertsson P, Fernández-Avilés F, Camiri P, Colombo A, Hamm C, et al (Grupo de Trabajo de la Sociedad Europea de Cardiología). Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Rev Esp Cardiol. 2005;58:679-728.
14. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol. 1997;30: 149-56.
15. De Queiroz Fernandes JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials. Am Heart J. 2004;148:937-43.
16. Wohrle J, Grebe OC, Nusser T, Al-Khayer E, Schaible S, Kochs M, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840-3.
17. Kakkar AK, Moustapha A, Hanley HG, Weiss M, Caldito G, Misra P, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31-4.
18. Hang Lee,C, Thye Ho K, Cheem Tan H. Instant dissolution of intracoronary thrombus by abciximab. Int J Cardiol. 2005;104:102-3.
19. Delcán Domínguez JL, García Fernández E, Guerrero Sanz JE. Rápida lisis de gran trombo coronario con abciximab. Rev Esp Cardiol. 2002;55:536.
20. Jiménez-Navarro MF, Curiel E, Hernández García JM, Alonso Briales JH, Domínguez Franco A, Gómez Doblas JJ, et al. Influencia de la diabetes mellitus en los resultados clínicos tras revascularización coronaria percutánea. Rev Esp Cardiol. 2002;55: 365-71.
21. Bourassa MG, Kip KE, Jacobs AK, Jones RH, Sopko G, Rosen A, et al. Is a strategy of intended percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? J Am Coll Cardiol. 1999;33:1627-36.
22. Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, et al. GUSTO IV-ACS. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS Investigators. Am Heart J. 2004;147:865-73.
23. Khan MA, Liu MW, Chio FL, Yates VB, Chapman GD, Misra VK, et al. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group. Catheter Cardiovasc Interv. 2001;52:40-4.
24. Simoons ML, Van den Brand M, Lincoff M, Harrington R, Van der Wieken R, Vahanian A, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J. 1999;20:1112-9.
25. Kini AS, Richard M, Suleman J, Perez N, Lee P, Fisher EA, et al. Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). Am J Cardiol. 2002;90:526-9.
26. Férez Santander SM, Márquez MF, Peña Duque MA, Ocaranza Sánchez R, De la Peña Almaguer E, Eid Lidt G. Daño miocárdico por reperfusión. Rev Esp Cardiol. 2004;57:9-21
27. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-35.
28. Antman EM. Presente y futuro del tratamiento antitrombótico en el síndrome coronario agudo. Rev Esp Cardiol. 2003;56:115-20.